Bitter Medicine Ahead for Drug Companies: Cutthroat competition and expiring patents may cast a pall

Bitter Medicine Ahead for Drug Companies: Cutthroat competition and expiring patents may cast a pall

Last year, it was hard to find companies with stronger vital signs than the big drugmakers. But investors are beginning to doubt whether drugmakers can continue to produce such robust results. One of the biggest problems is the shorter development cycle for new products.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bloomberg businessweek (Online) 1999-05 (3627), p.50
1. Verfasser: Amy Barrett in Philadelphia, with John Carey in Washington and Steve Brull in Los Angeles
Format: Magazinearticle
Sprache:eng
Schlagworte:
Competition
Industrywide conditions
Manycompanies
Pharmaceutical industry
Product development
Stock prices
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Last year, it was hard to find companies with stronger vital signs than the big drugmakers. But investors are beginning to doubt whether drugmakers can continue to produce such robust results. One of the biggest problems is the shorter development cycle for new products.
ISSN:0007-7135
2162-657X